List of Kerendia drug patents
Kerendia is owned by Bayer Hlthcare.
Kerendia contains Finerenone.
Kerendia has a total of 1 drug patent out of which 0 drug patents have expired.
Kerendia was authorised for market use on 09 July, 2021.
Kerendia is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Kerendia from 2025-07-09.
The generics of Kerendia are possible to be released after 12 April, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 9, 2026 |
| M (M) | Sep 1, 2025 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 2025-07-09
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET;ORAL
KERENDIA family patents
3
Uruguay
3
United States
2
Brazil
2
Taiwan
2
Japan
2
Malaysia
2
Hungary
2
European Union
1
Saudi Arabia
1
Chile
1
Peru
1
Poland
1
Dominican Republic
1
Canada
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Panama
1
Hong Kong
1
Costa Rica
1
Lithuania
1
China
1
Morocco
1
Germany
1
Netherlands
1
Honduras
1
Denmark
1
Croatia
1
Guatemala
1
Argentina
1
Spain
1
Mexico
1
New Zealand
1
Colombia
1
Australia
1
Russia
1
South Africa
1
Ecuador
1
Portugal
1
Tunisia
1
Cuba
1
Israel
1
Jordan
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic